OS for nivolumab versus placebo
The estimated post-recurrence survival was higher in CheckMate 238 than in EORTC 18,071 by 3.0% at 12 months, 3.7% by 24 months, 7.3% by 36 months, and 9.1% at 48 months. OS outcomes for nivolumab, placebo, and the placebo arm after adjustment are displayed in Fig. OS for nivolumab and placebo after adjusting for differences in subsequent treatments between the CheckMate 238 and EORTC 18,071 trials. Shaded areas indicate 95% CIs. NNT with adjuvant nivolumab versus placebo to obtain one additional overall survivor at 12, 24, 36, and 48 months using pooled data after adjusting for differences in subsequent treatments between the 2 trials. NNT was calculated as the reciprocal of the absolute risk reduction in OS and represented the number of patients needed to be treated with the intervention versus its comparator to obtain one additional overall survivor. After adjusting for the post-recurrence survival, the NNT with nivolumab to obtain one additional overall survivor compared with placebo was 10.4 (95% CI 5.4–104.1) at 12 months and decreased to 8.5 (95% CI 4.3–771.8) at 48 months (Fig. 